Severe community-acquired pneumonia: current management and future therapeutic alternatives

References

• Abubakar II, Tillmann T, Banerjee A. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;385(9963):117–171.
   PubMed Web of Science ®Google Scholar
• Jain S, Self WH, Wunderink RG, et al. CDC EPIC study team. Community-acquired pneumonia requiring hospitalization among U.S. Adults. N Engl J Med. 2015;373:415–427.
   PubMed Web of Science ®Google Scholar
• Lim WS, Eerden MM, van der, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–382.
   PubMed Web of Science ®Google Scholar
• Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British thoracic society diagnostic criteria. Am J Respir Crit Care Med. 2002;166:717–723.
   PubMed Web of Science ®Google Scholar
• Charles PG, Wolfe R, Whitby M, et al. Australian community-acquired pneumonia study collaboration, Grayson ML. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47:375–384.
   PubMed Web of Science ®Google Scholar
• Woodhead M, Welch CA, Harrison DA, et al. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC case mix programme database. Crit Care. 2006;10(Suppl 2):S1.
   PubMedGoogle Scholar
• Arnold FW, Wiemken TL, Peyrani P, et al. CAPO authors. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med. 2013;107(7):1101–1111.
   PubMed Web of Science ®Google Scholar
• Ito A, Ishida T, Tokumasu H, et al. Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort. BMC Pulm Med. 2017;17(1):78.
   PubMed Web of Science ®Google Scholar
• Walden AP, Clarke GM, McKechnie S, et al. ESICM/ECCRN GenOSept Investigators. Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. Crit Care. 2014 Apr 1;18(2):R58.
   PubMed Web of Science ®Google Scholar
• Vallés J, Diaz E, Martín-Loeches I, et al. Evolution over a 15-year period of the clinical characteristics and outcomes of critically ill patients with severe community-acquired pneumonia. Med Intensiva. 2016;40:238–245.
   PubMed Web of Science ®Google Scholar
• Antunes G, Evans SA, Lordan JL, et al. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J. 2002;20:990–995.
   PubMed Web of Science ®Google Scholar
• Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167:1655–1663.
   PubMed Web of Science ®Google Scholar
• Martínez R, Menéndez R, Reyes S, et al. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. Eur Respir J. 2011;37:393–399.
   PubMed Web of Science ®Google Scholar
• Ramírez P, Ferrer M, Martí V, et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med. 2011;39:2211–2217.
   PubMed Web of Science ®Google Scholar
• Menendez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 2008;63:447–452.
   PubMed Web of Science ®Google Scholar
• Sabatier C, Peredo R, Villagrá A, et al. Community-acquired pneumonia: a 7-years descriptive study. Usefulness of the IDSA/ATS 2007 in the assessment of ICU admission. Med Intensiva. 2010;34:237–245.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Ardanuy C, Tubau F, et al. Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax. 2010;65:77–81.
   PubMed Web of Science ®Google Scholar
• Mongardon N, Max A, Bouglé A, et al. Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Crit Care. 2012;16(4):R155.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Bodi M, Rodriguez A, et al. CAPUCI Study Investigators. Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. Chest. 2006;130(1):93–100.
   PubMed Web of Science ®Google Scholar
• Wiemkem T, Peyrani P, Bryant K, et al. Incidence of respiratory viruses in patients with community-acquired pneumonia admitted to the intensive care unit: results from the Severe Influenza Pneumonia Surveillance (SIPS) project. Eur J Clin Microbiol Infect Dis. 2013;32:705–710.
   PubMed Web of Science ®Google Scholar
• Choi SH, Hong SB, Ko GB, et al. Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med. 2012;186:325–332.
   PubMed Web of Science ®Google Scholar
• Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med. 2002;162:1849–1858.
   PubMed Web of Science ®Google Scholar
• Falguera M, Carratalà J, Ruiz-Gonzalez A, et al. Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. Respirology. 2009;14:105–111.
   PubMed Web of Science ®Google Scholar
• Micek ST, Kollef KE, Reichley RM, et al. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007;51:3568–3573.
   PubMed Web of Science ®Google Scholar
• Liapikou A, Polverino E, Cilloniz C, et al. Community-Acquired Pneumonia Organization (CAPO) Investigators. A worldwide perspective of nursing home-acquired pneumonia compared with community-acquired pneumonia. Respir Care. 2014;59:1078–1085.
   PubMed Web of Science ®Google Scholar
• Vallés J, Martin-Loeches I, Torres A, et al. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. Intensive Care Med. 2014;40:572–581.
   PubMed Web of Science ®Google Scholar
• Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164:637–644.
   PubMedGoogle Scholar
• Berjohn CM, Fishman NO, Joffe MM, et al. Treatment and outcomes for patients with bacteremic pneumococcal pneumonia. Medicine (Baltimore). 2008;87:160–166.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, García-Cabrera E, Diaz-Martín A, et al. Determinants of outcome in patients with bacteraemic pneumococcal pneumonia: importance of early adequate treatment. Scand J Infect Dis. 2010;42:185–192.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, et al. Adequate antibiotic therapy prior to ICU admission in patients with severe sepsis and septic shock reduces hospital mortality. Crit Care. 2015;19:302.
   PubMed Web of Science ®Google Scholar
• García-Gigorro R, de la Cruz Vigo F, Andrés-Esteban EM, et al. Impact on patient outcome of emergency department length of stay prior to ICU admission. Med Intensiva. 2017;41:201–208.
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America; American thoracic society. Infectious diseases society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.
   PubMed Web of Science ®Google Scholar
• Lim WS, Baudouin SV, George RC, et al. Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1–55.
   PubMed Web of Science ®Google Scholar
• Menéndez R, Torres A, Zalacaín R, et al. NEUMOFAIL Group. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med. 2005;172(6):757–762.
   PubMed Web of Science ®Google Scholar
• Bodí M, Rodríguez A, Solé-Violán J, et al. Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis. 2005;41:1709–1716.
   PubMed Web of Science ®Google Scholar
• Rodríguez A, Mendia A, Sirvent JM, et al. CAPUCI Study Group. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med. 2007;35:1493–1498.
   PubMed Web of Science ®Google Scholar
• Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001;161:1837–1842.
   PubMedGoogle Scholar
• Martínez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003;36:389–395.
   PubMed Web of Science ®Google Scholar
• Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with Pneumococcal bacteraemia. Am J Respir Crit Care Med. 2004;170:440–444.
   PubMed Web of Science ®Google Scholar
• Gattarello S, Borgatta B, Solé-Violán J, et al. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000–2013). Chest. 2014;146:22–31.
   PubMed Web of Science ®Google Scholar
• De la Calle C, Hg T-DLV, Morata L, et al. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: a propensity score analysis. J Infection. 2018;76:342–347.
   PubMed Web of Science ®Google Scholar
• Gattarello S, Lagunes L, Vidaur L, et al. Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case-control study. Crit Care. 2015 Sep;10(19):335.
   Google Scholar
• Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2012;55:371–380.
   PubMed Web of Science ®Google Scholar
• Sligl WI, Asadi L, Eurich DT, et al. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med. 2014;42(2):420–432.
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010;36:612–620.
   PubMed Web of Science ®Google Scholar
• Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009;33:153–159.
   PubMed Web of Science ®Google Scholar
• Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2004;125(2 Suppl):41S–50S.
   PubMed Web of Science ®Google Scholar
• Peyrani P, Wiemken TL, Metersky ML, et al. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization. Infect Dis (Lond). 2018;50:13–20.
   PubMed Web of Science ®Google Scholar
• Rosón B, Carratalà J, Fernández-Sabé N, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med. 2004 Mar 8;164(5):502–508.
   PubMedGoogle Scholar
• Pedro-Botet ML, Yu VL. Treatment strategies for Legionella infection. Expert Opin Pharmacother. 2009;10:1109–1121.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Sanchez-Rodriguez I, Simonetti AF, et al. Levofloxacin versus azithromycin for treating legionella pneumonia: a propensity score analysis. Clin Microbiol Infect. 2017;23(9):653–658.
   PubMed Web of Science ®Google Scholar
• Gacouin A, Le Tulzo Y, Lavoue S, et al. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy. Intensive Care Med. 2002;28:686–691.
   PubMed Web of Science ®Google Scholar
• Rello J, Gattarello S, Souto J, et al. Community-acquired pneumonia in Unidad de Cuidados intensivos 2 CAPUCI 2 study investigators. Community-acquired Legionella Pneumonia in the intensive care unit: impact on survival of combined antibiotic therapy. Med Intensiva. 2013;37:320–326.
   PubMed Web of Science ®Google Scholar
• Bopp LH, Baltch AL, Ritz WJ, et al. Activities of tigecycline and comparators against Legionella pneumophila and Legionella micdadei extracellularly and in human monocyte-derived macrophages. Diagn Microbiol Infect Dis. 2011;69:86–93.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Pechère JC, Routsi C, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis. 2008;46:1157–1164.
   PubMed Web of Science ®Google Scholar
• Flanders SA, Dudas V, Kerr K, et al. Effectiveness of ceftriaxone plus doxycycline in the treatment of patients hospitalized with community-acquired pneumonia. J Hosp Med. 2006;1:7–12.
   PubMed Web of Science ®Google Scholar
• Shoji H, Domenech A, Simonetti AF,Shoji H, Domenech A, Simonetti AF, et al. The Alere® BinaxNOW® pneumococcal urinary antigen test: diagnostic sensitivity for adult pneumococcal pneumonia and relationship to specific serotypes. J Clin Microbiol. 2018 Jan 24;56(2). pii: e00787-17. doi: 10.1128/JCM.00787-17.
   Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–377.
   PubMed Web of Science ®Google Scholar
• Zuckerman JM, Kaye KM. The newer macrolides. Azithromycin and clarithromycin. Infect Dis Clin North Am. 1995;9:731–745.
   PubMed Web of Science ®Google Scholar
• Ruiz J, Ramirez P, Gordon M, et al. mAntimicrobial stewardship programme in critical care medicine: a prospective interventional study. Med Intensiva. 2018;42:266–273.
   PubMed Web of Science ®Google Scholar
• Sader HS, Flamm RK, Streit JM, et al. Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program. Antimicrob Agents Chemother. 2015;59:2458–2461.
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Iaconis JP, Sahm DF. Comparative in vitro activities of ceftaroline and ceftriaxone against bacterial pathogens associated with respiratory tract infections: results from the AWARE surveillance study. J Antimicrob Chemother. 2016;71:3459–3464.
   PubMed Web of Science ®Google Scholar
• Taboada M, Melnick D, Iaconis JP, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2016;71:862–870.
   PubMed Web of Science ®Google Scholar
• Nilius AM, Shen LL, Hensey-Rudloff D, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother. 2003;47:3260–3269.
   PubMed Web of Science ®Google Scholar
• Thabit AK, Crandon JL, Nicolau DP. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. Int J Antimicrob Agents. 2016;48:535–541.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02679573
   Google Scholar
• Lee YM, Hong HL, Kim HS, et al. Fluoroquinolone resistance of Streptococcus pneumoniae isolates causing invasive disease: special focus on zabofloxacin. Diagn Microbiol Infect Dis. 2016;86: 181–183. Kim T, Park SJ, Chong YP, Park KH.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Wada H, Rossios C, et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition. J Pharmacol Exp Ther. 2013;345:76–84.
   PubMed Web of Science ®Google Scholar
• File TM Jr, Rewerska B, Vucinic-Mihailovic V, et al. SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin Infect Dis. 2016;63(8):1007–1016.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Rhomberg PR, Huband MD, et al. Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). Diagn Microbiol Infect Dis Diagn Microbiol Infect Dis. 2018;90:143–147.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02531438?cond=Omadacycline&rank=3
   Google Scholar
• Montón C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J. 1999;14:2:18–20.
   Web of Science ®Google Scholar
• Salluh JIF, Bozza FA, Soares M, et al. Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity. Chest. 2008;134:947–954.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Calbo E, Pascual V, et al. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J. 2007 Nov;30(5):951–956.
   PubMed Web of Science ®Google Scholar
• Tagami T, Matsui H, Horiguchi H, et al. Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients. Eur Respir J. 2015;45:463–472.
   PubMed Web of Science ®Google Scholar
• Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171:242–248.
   PubMed Web of Science ®Google Scholar
• Mikami K, Suzuki M, Kitagawa H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung. 2007;185:249–255.
   PubMed Web of Science ®Google Scholar
• Snijders D, Daniels JM, De Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010 May 1;181(9):975–982.
   PubMed Web of Science ®Google Scholar
• Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9782):2023–2030.
   PubMed Web of Science ®Google Scholar
• Fernández-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care. 2011 Mar 15;15(2):R96.
   PubMed Web of Science ®Google Scholar
• Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313:677–686.
   PubMed Web of Science ®Google Scholar
• Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385(9977):1511–1518.
   PubMed Web of Science ®Google Scholar
• Siempos II, Vardakas KZ, Kopterides P, et al. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother. 2008;62:661–668.
   PubMed Web of Science ®Google Scholar
• Nie W, Zhang Y, Cheng J, et al. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS One. 2012;7(10):e47926.
   PubMed Web of Science ®Google Scholar
• Cheng M, Pan ZY, Yang J, et al. Corticosteroid therapy for severe community-acquired pneumonia: a meta-analysis. Respir Care. 2014;59:557–563.
   PubMedGoogle Scholar
• Horita N, Otsuka T, Haranaga S, et al. Adjunctive systemic corticosteroids for hospitalized community-acquired pneumonia: systematic review and meta-analysis 2015 update. Sci Rep. 2015;5:14061.
   PubMed Web of Science ®Google Scholar
• Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med. 2015;163:519–528.
   PubMed Web of Science ®Google Scholar
• Wan YD, Sun TW, Liu ZQ, et al. Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest. 2016;149:209–219.
   PubMed Web of Science ®Google Scholar
• Bi J, Yang J, Wang Y, et al. and safety of adjunctive corticosteroids therapy for severe community-acquired pneumonia in adults: an updated systematic review and meta-analysis. PLoS One. 2016 Nov 15;11(11):e0165942.
   PubMed Web of Science ®Google Scholar
• Wu WF, Fang Q, He GJ. Efficacy of corticosteroid treatment for severe community-acquired pneumonia: a meta-analysis. Am J Emerg Med. 2017 Jul 15:pii: S0735-6757(17)30577-6 Epub ahead of print. doi:10.1016/j.ajem.2017.07.050.
   Web of Science ®Google Scholar
• Marti C, Grosgurin O, Harbarth S, et al. Adjunctive corticotherapy for community acquired pneumonia: a systematic review and meta-analysis. PLoS One. 2015;10:e0144032.
   PubMed Web of Science ®Google Scholar
• Briel M, Spoorenberg SMC, Snijders D, et al. Ovidius study group; Capisce study group; STEP study group. Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data meta-analysis. Clin Infect Dis. 2018;66:346–354.
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Bonten MJ, Boersma WG, et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT). Neth J Med. 2018;76:4–13.
   PubMed Web of Science ®Google Scholar
• Shankar-Hari M, Spencer J, Sewell WA, et al. Bench-to-bedside review: immunoglobulin therapy for sepsis—biological plausibility from a critical care perspective. Crit Care. 2012;16:206.
   PubMed Web of Science ®Google Scholar
• Alejandria MM, Lansang MA, Dans LF, et al. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013;9:CD001090.
   PubMed Web of Science ®Google Scholar
• Berlot G, Vassallo MC, Busetto N, et al. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J Crit Care. 2012;27:167–171.
   PubMed Web of Science ®Google Scholar
• de la Torre MC, Bolíbar I, Vendrell M, et al. Serum immunoglobulins in the infected and convalescent phases in community-acquired pneumonia. Respir Med. 2013;107:2038–2045.
   PubMed Web of Science ®Google Scholar
• de la Torre MC, Palomera E, Serra-Prat M, et al. IgG2 as an independent risk factor for mortality in patients with community-acquired pneumonia. J Crit Care. 2016;35:115–119.
   PubMed Web of Science ®Google Scholar
• Tagami T, Matsui H, Fushimi K, et al. Intravenous immunoglobulin and mortality in pneumonia patients with septic shock: an observational nationwide study. Clin Infect Dis. 2015;61:385–392.
   PubMed Web of Science ®Google Scholar
• Welte T, Dellinger RP, Ebelt H, et al. Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study. Respir Med. 2015;109(6):758–767.
   PubMed Web of Science ®Google Scholar
• Welte T, Dellinger RP, Ebelt H, et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patientswith severe community-acquired pneumonia: a randomized, placebo-controlled,double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med. 2018;44:438–448.
   PubMed Web of Science ®Google Scholar
• Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004;109(21 Suppl 1):II18–26.
   PubMed Web of Science ®Google Scholar
• Viasus D, Garcia-Vidal C, Simonetti AF, et al. The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. BMJ Open. 2015 Jan 6;5(1):e006251.
   PubMed Web of Science ®Google Scholar
• Chopra V, Rogers MA, Buist M, et al. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med. 2012;125:1111–1123.
   PubMed Web of Science ®Google Scholar
• Havers F, Bramley AM, Finelli L, et al. Statin use and hospital length of stay among adults hospitalized with community-acquired Pneumonia. Clin Infect Dis. 2016;62:1471–1478.
   PubMed Web of Science ®Google Scholar
• Gupta N, Krasnodembskaya A, Kapetanaki M, et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax. 2012;67:533–539.
   PubMed Web of Science ®Google Scholar
• Monsel A, Zhu YG, Gennai S, et al. Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice. Am J Respir Crit Care Med. 2015;192:324–336.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03158727
   Google Scholar